These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37354495)

  • 1. IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
    Nakayama Y; Watanabe R; Yamamoto W; Ebina K; Hirano T; Kotani T; Shiba H; Katayama M; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Murakami K; Murata K; Ito H; Tanaka M; Matsuda S; Morinobu A; Hashimoto M
    Rheumatology (Oxford); 2024 Feb; 63(2):349-357. PubMed ID: 37354495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study.
    Nakayama Y; Onishi A; Yamamoto W; Yoshikawa A; Shiba H; Yoshida N; Son Y; Shirasugi I; Maeda T; Katsushima M; Hashimoto M; Etani Y; Itami T; Nozaki Y; Onizawa H; Fujii T; Murakami K; Murata K; Tanaka M; Matsuda S; Morinobu A
    Clin Exp Med; 2024 May; 24(1):97. PubMed ID: 38727756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
    Onishi A; Yamada H; Yamamoto W; Watanabe R; Hara R; Katayama M; Okita Y; Maeda Y; Amuro H; Son Y; Yoshikawa A; Hata K; Hashimoto M; Saegusa J; Morinobu A
    Rheumatology (Oxford); 2024 Nov; 63(11):3065-3073. PubMed ID: 37988163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.
    Padula AS; Pappas DA; Fiore S; Blachley TS; Ford K; Emeanuru K; Kremer JM
    Arthritis Res Ther; 2022 Dec; 24(1):276. PubMed ID: 36544236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study.
    Nakayama Y; Hashimoto M; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A
    Scand J Rheumatol; 2022 Nov; 51(6):431-440. PubMed ID: 34511031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
    Skaarup L; Ingrid E; Sepriano A; Nikiphorou E; Østgård R; Lauper K; Grosse-Michaelis I; Kloppenburg M; Glintborg B; Liew DFL; Kragstrup TW
    Drug Saf; 2024 Nov; 47(11):1075-1093. PubMed ID: 39012469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
    Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
    Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
    Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of biologic and non-biologic antirheumatic drugs on anaemia markers in 153,788 patients with rheumatoid arthritis: New evidence from real-world data.
    Paul SK; Montvida O; Best JH; Gale S; Pethoe-Schramm A; Sarsour K
    Semin Arthritis Rheum; 2018 Feb; 47(4):478-484. PubMed ID: 28947313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis.
    Saito K; Yoshida S; Ebina H; Miyata M; Suzuki E; Kanno T; Sumichika Y; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
    PLoS One; 2024; 19(7):e0306714. PubMed ID: 38990897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Hernández-Cruz B; Otero-Varela L; Freire-González M; Busquets-Pérez N; García González AJ; Moreno-Ramos M; Blanco-Madrigal JM; Manrique-Arija S; Perez-Pampin E; Ruiz-Montesino D; Sánchez-Alonso F; Sanchez-Piedra C; Castrejón I;
    Ann Rheum Dis; 2024 Aug; 83(9):1189-1199. PubMed ID: 38594056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
    Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
    Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Lauper K; Iudici M; Mongin D; Bergstra SA; Choquette D; Codreanu C; Cordtz R; De Cock D; Dreyer L; Elkayam O; Hauge EM; Huschek D; Hyrich KL; Iannone F; Inanc N; Kearsley-Fleet L; Kristianslund EK; Kvien TK; Leeb BF; Lukina G; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Strangfeld A; Verschueren P; Courvoisier DS; Finckh A
    Ann Rheum Dis; 2022 Oct; 81(10):1358-1366. PubMed ID: 35705376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.
    Watanabe R; Ebina K; Gon T; Okano T; Murata K; Murakami K; Maeda Y; Jinno S; Shirasugi I; Son Y; Amuro H; Katayama M; Hara R; Hata K; Yoshikawa A; Yamamoto W; Tachibana S; Hayashi S; Etani Y; Katsushima M; Fukumoto K; Yamada S; Hashimoto M
    Rheumatology (Oxford); 2024 Sep; 63(9):2418-2426. PubMed ID: 38724245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
    Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
    RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.
    Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH
    Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
    Jinno S; Onishi A; Hattori S; Dubreuil M; Ueda Y; Nishimura K; Okano T; Yamada H; Yamamoto W; Murata K; Onizawa H; Ebina K; Maeda Y; Son Y; Amuro H; Hara R; Hata K; Shiba H; Katayama M; Watanabe R; Hashimoto M; Saegusa J
    Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38317442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis.
    Fang YF; Liu JR; Chang SH; Kuo CF; See LC
    Int J Rheum Dis; 2022 Nov; 25(11):1254-1262. PubMed ID: 35923107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.